Kazia Therapeutics Reports Encouraging Preliminary Responses for Paxalisib in Late-Stage Triple-Negative Breast Cancer Study

summarizeSummary

Kazia Therapeutics announced encouraging preliminary clinical responses, including partial and complete metabolic responses, from its Phase 1b study of paxalisib in late-stage metastatic triple-negative breast cancer.

check_boxKey Events

• Encouraging Preliminary Clinical Responses

  The Phase 1b study of paxalisib in late-stage metastatic triple-negative breast cancer (TNBC) reported two partial responses (PRs) in evaluable patients and one confirmed complete metabolic response (CR) in a patient treated under an expanded access program.

• Significant Efficacy in Challenging Indication

  Responses were observed in patients with visceral disease and multi-organ metastases, including a complete metabolic response in a patient who had previously progressed on standard pembrolizumab/chemotherapy, which is considered rare in metastatic TNBC.

• Favorable Safety and Tolerability Profile

  Paxalisib demonstrated a generally favorable safety and tolerability profile when combined with pembrolizumab and chemotherapy, with most adverse events deemed unrelated to paxalisib.

• Advancing Clinical Development

  The company plans to activate additional clinical sites by April 2026, targeting enrollment of twelve TNBC patients by the end of 2026, with topline data anticipated in early 2027.

auto_awesomeAnalysis

Kazia Therapeutics announced encouraging preliminary clinical responses from its ongoing Phase 1b study of paxalisib in combination therapy for late-stage metastatic triple-negative breast cancer (TNBC). The observed partial responses in two evaluable patients and a confirmed complete metabolic response in a patient previously treated with pembrolizumab/chemotherapy are significant, as confirmed complete responses in this aggressive cancer type are exceedingly rare, especially in patients who have progressed on standard therapies. While the data is preliminary and from a small patient cohort, it provides a strong positive signal for paxalisib's potential to enhance existing immunotherapy regimens. The favorable safety profile and plans to expand clinical sites further support the drug's development trajectory.